Explore the words cloud of the BRAVE project. It provides you a very rough idea of what is the project "BRAVE" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||3˙378˙225 €|
|EC max contribution||2˙364˙757 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2020-01-01 to 2021-12-31|
Take a look of project's partnership.
~500 million blood draws are missed every year, with great consequences. The most important complication is nerve injury, occurring in approximately a million cases. Nerve injury can even lead to permanent disablement. In addition to direct complications for patients, blood drawing presents real issues for clinical laboratories. Blood drawing is the only step in the blood testing process that is not automated. The majority of lab errors occur during the blood draw, accounting for more than an estimated 160M diagnostic errors leading to misdiagnosis and -treatment plus ~€10B in yearly costs for society. Furthermore, operational costs for laboratories are high and blood drawing personnel is difficult to find. The VD-1 can autonomously draw blood from patients. Willingness to use a device is very high. The majority of patients visiting the hospital for a blood draw are willing to try the VD-1. For laboratories, the VD-1 will reduce diagnostic errors because of standardization of the process. Moreover, labs can save on operational cost and increase capacity. The benefits are clear to our (European) potential customers, who have invested, signed letters of intent to purchase and are keen to collaborate. The technology of the VD-1 (three patents applied) consists of real-time image recognition software based on AI, tested on a vast number of images, able to create a 3D vein image despite difficult conditions. Advanced robotic positioning ensures high needle precision, impossible to achieve by a human. For ultimate safety, the needle position can be adjusted based on patient movements. The overall objectives of the BRAVE project are to optimize prototype 2 and test this optimization in the BRAVE trial, subsequently industrialize and validate the positioning system with as result the fabrication of the 0-series.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAVE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BRAVE" are provided by the European Opendata Portal: CORDIS opendata.
MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINERead More
CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.Read More
First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchainRead More